C&L: Frost resigns at ImClone

ImClone Systems' chief scientific officer Philip Frost has resigned.

Astex Therapeutics has hired John Aston as CFO and a member of its board of directors.

John Fess has been named CEO of Blue Heron Biotechnology. Fess succeeds John Mulligan, Ph.D., Blue Heron's founder who will become the company's board chairman and chief scientific officer.

The Pittsburgh Life Sciences Greenhouse has named John W. Manzetti as its new president and CEO.

Alpharma has hired Stefan Aigner, MD, as executive vice president, corporate and business development.

Thoratec has named David V. Smith executive vice president and CFO.

CytoGenix has appointed Pamela Schertz as interim CFO.

NovaDel Pharma has appointed David H. Bergstrom, Ph.D. as COO.

Mylan Laboratories has named David F. Mulder to the position of senior vice president, corporate and business development.

Spirogen has named J. Barrie Ward as a chairman of the board of directors and Christopher J. Pugh as chief business officer.

StemCells announced that Stephen Huhn, M.D., has accepted a position as vice president and head of the neural program, effective January 1. Dr. Huhn will be on leave from his positions as associate professor of neurosurgery and chief of pediatric neurosurgery at Stanford University School of Medicine. Ann Tsukamoto, Ph.D., formerly vice president, research and development, has been promoted to the newly created position of chief operating officer and retains overall responsibility for the company's research and development efforts. Maria Millan, M.D., head of the liver program, has been appointed a vice president of the company. Dr. Alan Jacobs, former chief medical officer and vice president, clinical research, neural program, has left the company.

Medivation has named Sue Wollowitz, Ph.D., as vice president, chemistry and manufacturing.

ACCU-BREAK Pharmaceuticals has named Lawrence Rosenthal vice president of the company and president of its wholly-owned subsidiary, ACCU-BREAK Generics.

Bayhill Therapeutics has named Paul Westberg to the newly created position of vice president of business development.

Archemixhas named James McArdle, Ph.D., as vice president of chemistry, manufacturing and controls.

Victory Pharma announced that Deborah Wild has joined the company as vice president, manufacturing operations and quality systems.

INC Research has appointed Tetsushi Inada, Ph.D., as senior liaison officer to Japan.

Cerimon Pharmaceuticals has named Ayse Kocak vice president of marketing.

Ambit Biosciences has named Kerry Kelly, J.D., former associate general counsel for The Scripps Research Institute, as vice president and general counsel.

Cephalon has appointed Raj Khankari, Ph.D. as general manager of CIMA LABS, its wholly owned drug delivery subsidiary.

Dr. Donald Margouleff has joined Daxor as director of nuclear medicine.

Musculoskeletal Clinical Regulatory Advisers announced that Angela Byland has joined the firm as director, biologics regulatory affairs. Teresa M. Schroeder has joined the firm as director, spine clinical affairs.

Potentia Pharmaceuticals has named Armen H. Tashjian, Jr., M.D. to its scientific advisory board.

IRX Therapeutics announced that Jean Louis Lefebvre, M.D., ENT and head and neck surgeon has joined its medical advisory board.

Dr. Clive Patience Ph.D. has joined Sernova's scientific advisory board.

King Pharmaceuticals' board of directors has appointed Brian A. Markison to succeed Ted G. Wood as the chairman of the company's board.

Edward T. Shonsey, CEO of Diversa Corporation, has joined MetaMorphix's board of directors.

LAB Research has elected Stephen R. Farrell to its board of directors.

Ilypsa has named Samuel R. Saks, M.D., CEO of Jazz Pharmaceuticals, to its board of directors. 

Allergan has appointed Dr. Deborah Dunsire to the company's board of directors.

PeriCor Therapeutics has named Larry G. Pickering to the company's board of directors.

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.